Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin’s lymphoma cells
- 195 Downloads
Hodgkin’s lymphoma (HL) is a malignant disease of the lymphatic system. The therapy has been improved during the last decades but there are still patients who cannot be cured, and the therapy is associated with several adverse late effects. Therefore, we asked which genes might be involved in the chemotherapy resistance of HL cells. We observed that HL cells became more resistant against cisplatin after treatment with cobalt chloride. Therefore, we analyzed which genes were differentially expressed between cells incubated in medium with or without cobalt chloride. We found several genes which were up- or downregulated in the presence of cobalt chloride and might be involved in the modulation of chemotherapy resistance. Cobalt chloride is a hypoxia-mimetic agent. Therefore, we tested chemo-resistance and gene expression of HL cells under hypoxic conditions and confirmed the results from the cobalt chloride experiments. Taken together, activation of the hypoxia pathway led to altered gene expression and drug resistance of HL cells. Differentially expressed genes might be interesting targets for the development of future treatment strategies against drug-resistant HL.
KeywordsHodgkin’s lymphoma Drug resistance Hypoxia Cobalt chloride Gene expression
This work was supported by a fellowship from the Konrad-Adenauer-Stiftung (SK) and the Wilhelm-Roux-Program of the Martin Luther University Halle-Wittenberg (MSS).
S. K. and I. V. performed the experiments; M. S. S. designed the research; S. K. and M. S. S analyzed and discussed the data; S. K. and M. S. S wrote the paper, and L. K. contributed to the discussion.
Compliance with ethical standards
Conflicts of interest
- 1.Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009: 491–6.Google Scholar
- 44.Li F, Huang L, Su XL, et al. Inhibition of nuclear factor-κB activity enhanced chemosensitivity to cisplatin in human lung adeno-carcinoma A549 cells under chemical hypoxia conditions. Chin Med J (Engl). 2013;126:3276–82.Google Scholar
- 52.Su J, Wu S, Tang W, et al. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling. Mol Carcinog. 2015. doi: 10.1002/mc.22430.Google Scholar
- 55.Kurch L, Hasenclever D, Tchavdarova L, et al. Non-FDG-avid areas inside a tumour mass in Paediatric Hodgkin Lymphoma (PHL) patients—a new risk factor?. EJNM. 2014; 41 (Suppl 2), Abstract.Google Scholar
- 69.Zhao WJ, Deng BY, Wang XM, et al. XIAP associated factor 1 (XAF1) represses expression of X-linked inhibitor of apoptosis protein (XIAP) and regulates invasion, cell cycle, apoptosis, and cisplatin sensitivity of ovarian carcinoma cells. Asian Pac J Cancer Prev. 2015;16:2453–8.CrossRefPubMedGoogle Scholar